ReviewClinical pharmacology and therapeutics2022

Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations.

Derek Z Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.